Professional
Added to YB: 2024-10-22
Pitch date: 2024-09-30
ARGX [bullish]
argenx SE
+57.47%
current return
Author Info
No bio for this author
Company Info
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
Market Cap
EUR 55.4B
Pitch Price
EUR 540.39
Price Target
N/A
Dividend
N/A
EV/EBITDA
72.01
P/E
38.93
EV/Sales
14.00
Sector
Biotechnology
Category
growth
Baron Health Care Fund Portfolio Holding: argenx SE
ARGX: Vyvgart gains 2nd approval for CIDP, strong launch expected. Competitor Uplinza disappoints in myasthenia gravis. Multiple upcoming catalysts in myositis, Sjogren's, MMN, and subQ formulation to drive growth. Biotech focused on autoimmune disorders with positive outlook.
Read full article (1 min)